The two-dose vaccine developed by Chinese Sinovac is less effective against the Omicron coronavirus strain compared to other variants even after a booster dose produced by Pfizer and BioNTech, according to the latest study published on Friday.
The research, conducted by multiple institutions across the globe and yet to be peer-reviewed, concluded that recipients of this vaccine combo might need an additional booster dose to hit antibody levels to be protected versus Omicron.
Hong Kong, where this vaccine combo is massively used, previously reported that the two-dose Sinovac vaccine failed to produce sufficient antibody response to protect from the Omicron variant.
